Table 3 Frequency of KIR-HLA combinations, and HLA class-I ligands among patients with lung cancer and healthy controls.
From: KIR-HLA gene diversities and susceptibility to lung cancer
KIR/HLA | Healthy controls | Lung cancer | Lung cancer versus HC | |
|---|---|---|---|---|
n = 448 | n = 232 | p value | OR (95% CI) | |
%F (N + /n) | F% (N + /n) | |||
KIR-binding motif | ||||
HLA-C1 | 74.2 (124/167) | 81.5 (53/65) | ||
HLA-C2 | 73.6 (123/167) | 72.3 (47.65) | ||
HLA-Bw4 | 62.1 (95/153) | 48.1 (25/52) | ||
Bw4T80 | 45.7 (70/153) | 44.2 (23/52) | ||
Bw4I80 | 16.3 (25/153) | 3.8 (2/52) | 0.018 | 0.2 (0.047–0.9) |
HLA-A3/A11 | 39.2 (31/79) | 38.1 (24/63) | ||
HLA-A23/24/25/32 | 49.3 (39/79) | 44.4 (28/63) | ||
KIR-HLA combination | ||||
3DL2 + A3/A11 | 39.2 (31/79) | 38.1 (24/63) | ||
2DL1 + C2 | 71.8 (120/167) | 72.3 (47/65) | ||
2DL3 + C1 | 68.8 (115/167) | 69.2 (45/65) | ||
2DL2 + C1 | 38.3 (64/167) | 55.3 (36/65) | 0.026 | 1.99 (1.11–3.56) |
3DL1 + Bw4 | 62.0 (95/153) | 44.2 (23/52) | 0.014 | 0.48 (0.25–0.91) |
2DS1 + C2 | 26.6 (45/169) | 27.7 (18/65) | ||
2DS2 + C1 | 34.7 (58/167) | 50.8 (33/65) | 0.036 | 1.93 (1.08–3.46) |
3DS1 + Bw4 | 20.2 (31/153) | 15.3 (8/52) | ||
